PCSK9 inhibitor Evolocumab alleviates atherosclerosis progression by suppressing endothelial cell injury via the ROS/MAPK pathway
General physiology and biophysics · 2026 · 45 (02) · 153-165
DOI: 10.4149/gpb_2025043 ↗Kurz gefasst
Fachartikel in der Zeitschrift General physiology and biophysics, 2026. Verfasst von Menghuai Ma und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Fuwai Yunnan Hospital, Chinese Academy of Medical Sciences, Affiliated Cardiovascular Hospital of Kunming Medical Universit…. Hauptthemen laut MEDLINE: Atherosclerosis, PCSK9 Inhibitors, Antibodies, Monoclonal, Humanized, Reactive Oxygen Species.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Fuwai Yunnan Hospital, Chinese Academy of Medical Sciences, Affiliated Cardiovascular Hospital of Kunming Medical University, Kunming, China.
Zitieren
APA
Ma, M., Liu, F., Yin, X., Yue, J., Duan, Y., & Tang, J. (2026). PCSK9 inhibitor Evolocumab alleviates atherosclerosis progression by suppressing endothelial cell injury via the ROS/MAPK pathway. General physiology and biophysics, 45(02), 153-165. https://doi.org/10.4149/gpb_2025043
Vancouver
Ma M, Liu F, Yin X, Yue J, Duan Y, Tang J. PCSK9 inhibitor Evolocumab alleviates atherosclerosis progression by suppressing endothelial cell injury via the ROS/MAPK pathway. General physiology and biophysics. 2026;45(02):153-165. doi:10.4149/gpb_2025043
BibTeX
@article{Ma2026,
author = {Ma, Menghuai and Liu, Fan and Yin, Xiaomei and Yue, Jianhong and Duan, Yanhua and Tang, Jiong},
title = {PCSK9 inhibitor Evolocumab alleviates atherosclerosis progression by suppressing endothelial cell injury via the ROS/MAPK pathway},
journal = {General physiology and biophysics},
year = {2026},
volume = {45},
number = {02},
pages = {153--165},
doi = {10.4149/gpb_2025043}
}
EUVIMED